Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIC5-15 in Alzheimer's Disease
NCT00470418Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing NIC5-15 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events at 7 weeks. Started Jan 2007; status: completed.
02
Drugs
pinitol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00470418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470418.